Medical Condition: Chronic Obstructive Pulmonary Disease (COPD)
Purpose of Study: To evaluate the safety and effectiveness of benralizumab in patients with moderate to very severe COPD who have a history of COPD flare-ups
Eligibility Requirements:
- 40 to 85 years old
- History of moderate to very severe COPD
- History of smoking
Treatment with an inhaled corticosteroid and at least one other controller medication for at least 12 months. Examples of medications that may qualify for the study include, but are not limited to Advair Diskus®, Symbicort®, Breo Ellipta®, Serevent®, Foradil®, Arcapta Neohaler®, Anoro Ellipta®, Spiriva HandiHaler®, and Tudorza Pressair® .
At least 2 COPD flare-ups in the past 12 months requiring treatment with a systemic corticosteroid and/or antibiotics. Examples of systemic corticosteroids include, but are not limited to prednisone, prednisolone, methylprednisolone, and dexamethasone.
OR
At least 1 COPD flare-up that required hospitalization in the past 12 months.
Compensation: Compensation will be provided.
Please contact Heather Kohler at 971-220-2208, extension 2, for additional information about the research study.
